However, with solid evidence of their effectiveness in hematological and non-hematological preclinical tumor models and unique character to detect the expression levels of tumor-specific peptide/MHC complexes on the surface of tumor cells, TCR-like antibodies may represent an ideal next step for cancer immunotherapy. This evidence concerns the gene HLA-C and cancer.